29.05.2022, 1793 Zeichen
A very fine week for our ATX TR with Do&Co on top and all five days up. News came from Marinomed, Fabasoft, CA Immo, Immofinanz, Porr, Verbund, UBM, Valneva, EVN and Petro Welt Technologies.
BSNgine weekly Spitout: The ATX TR up 5,06% to 6.969,47 points this week. Year-to-date the ATX TR is now at -11,2%. Up to now there were 52 days with a positive and 51 with a negative gain. From the year-high we are 15,54% away, from the low 17,35%. Statistically the best weekday so far 2022 is Wednesday with 0,72%, the weakest is Monday with -0,91%.
These are the best-performers this week: DO&CO 10,8% in front of Wienerberger 8,85% and Verbund 8,66%. And the following stocks performed worst: UBM -7,67% in front of SBO -3,78% and Frequentis -3,36%.
Further highlights this week: DO&CO for 5 days in a row up (10,8% gain from 78,7 to 87,2), also Wienerberger 3 days up (6,19% gain from 24,56 to 26,08), Bawag 3 days up (3,47% gain from 46,62 to 48,24), CA Immo 3 days up (4,79% gain from 29,25 to 30,65), Lenzing 3 days up (5,67% gain from 82,9 to 87,6), Palfinger 3 days up (3,18% gain from 23,55 to 24,3), VIG 3 days up (2,23% gain from 22,45 to 22,95), voestalpine 3 days up (2,95% gain from 27,1 to 27,9).
Best-performers year-to-date as of now: SBO 105,49% (last year: -0,48 percent) followed by AT&S 27,71% (last year: 65,9 percent) and DO&CO 17,68% (last year: 10,93 percent). And the worst-performing stocks year-to-date: RBI -52,36% (Vorjahr: 55,16 percent), followed by Semperit -31,23% (Vorjahr: 20,58 percent) and Erste Group -29,6% (Vorjahr: 65,8 percent).
High above the MA200: SBO 59,78%, AT&S 28,86% and DO&CO 12,33%.
Down under the MA200: RBI -40,16%, Semperit -25,71% and Palfinger -23,36%.
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (28/05/2022)
Wiener Börse Party #649: 5 Jahre Börser-Rolemodel Frequentis, AT&S im Glück, ATX vor ev. 5. All-time-High in kurzer Zeit
Valneva
Valneva ist ein Impfstoffunternehmen, das sich auf die Entwicklung und Vermarktung von prophylaktischen Impfstoffen gegen Infektionskrankheiten mit hohem ungedeckten medizinischen Bedarf spezialisiert hat.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner